COVID-19 Vaccine for Children: Clinical Considerations for Physicians


… the Clinical Considerations of the PfizerBioNTech COVID-19 Vacccine CME Session featuring representatives for the Centers for Disease Control is available for members to access on-demand. Once you have viewed the session, complete the SurveyMonkey link to receive CME Credit.

Continuing Medical Education Information

Course Description:

This module will provide an in-depth discussion on the recent availability of COVID-19 vaccinations for children ages 5-11.


Rachel Gorwitz, M.D., MPH, FAAP, serves as the Associate Director for Epidemiologic Science at the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Dr. Gorwitz is currently supporting the CDC COVID-19 Vaccine Task Force as Deputy Chief Medical Officer. She is a board-certified pediatrician with expertise in infectious disease epidemiology.


Chris Duggar, MPH, works in Fort Collins, CO for the U.S. Centers for Disease Control & Prevention. Since 2020 he has led CDC’s Vaccine Distribution, Awardee, and Partner Support section for the COVID-19 Response in the Vaccine Task Force.

Chris has served in a number of roles with the CDC including the National Center for Immunization and Respiratory Diseases (NCIRD)’s Influenza Division, Acting Branch Chief for Global Health’s Country Strategy and Implementation Branch, overseas as the CDC Deputy Country Director in Tbilisi, Georgia, and as the Immunization program Public Health Advisor in Colorado. Prior to his field career Chris worked with the Immunization Program, the National Stockpile, as well as the Influenza Division building local, national, and international public health programs. As a graduate of the Presidential Management Fellowship Chris has worked not only with CDC but also the Food & Drug Administration, HHS, DOD, and collaborated with multiple government partners.


At the end of this module physicians will be able to:

  1. Describe dosage, storage, logistical and distribution information to physicians regarding the PfizerBioNTech COVID-19 Vaccine for children ages 5-11.
  2. Discuss reported adverse effects including myocarditis and multisystem inflammatory syndrome.
  3. Provide new guidance related to potential boosters and age considerations.

Disclosure: All individuals involved in the planning and delivery of materials disclose they have no relevant relationships. 

Commercial Support: There is no commercial support associated with this activity.

None of the planners or faculty for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

The Kentucky Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Kentucky Medical Association designates this enduring internet activity for 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: Physicians in the Commonwealth of Kentucky

Estimated Time to Complete: This module will take approximately 1.0 hours to complete

Method of Participation Used: Participants will view and listen to a recorded panel discussion.

Hardware/Software Requirements: High speed internet connection

Meeting Planner: Miranda Mosley, Heather Lathan

Provider Contact Information: Miranda Mosley, Kentucky Medical Association

Copyright: There is no copyright associated with this activity

Release Date: November 2021


Click here to access the activity